Disseminated mucormycosis

IDCases 2026 Open access

Read full text
Authors: Christopher V. Radcliffe, Elizabeth E. Tremblay, Francisco J Machiavello Roman
DOI: 10.1016/j.idcr.2026.e02514
Cited by: 0
References: 2

Abstract

•New skin lesions in stem cell transplant recipients warrant a thorough work up.•Confirmation of invasive mucormycosis requires a tissue biopsy.•Amphotericin B remains the first-line empiric antifungal for mucormycosis.•Reconstitution of host immunity is essential for favorable mucormycosis outcomes.

Fields of Study & Subjects

Antifungal resistance and susceptibility Fungal Infections and Studies Infectious Diseases and Mycology

Publication details

Journal / source
IDCases
Volume
43
Pages
e02514–e02514
Publication date
1 January 2026
Language
EN